ArticleLeukemia & lymphoma2014
Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.
Article in Leukemia & lymphoma, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.The Cochrane database of systematic reviews · 2015Pooled it
- Spectrophotometric Study of Charge-Transfer Complexes of Ruxolitinib with Chloranilic Acid and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone: An Application to the Development of a Green and High-Throughput Microwell Method for Quantification of Ruxolitinib in Its Pharmaceutical Formulations.Molecules (Basel, Switzerland) · 2023Article
- Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in TurkeyTurkish journal of medical sciences · 2021Article
- Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research.Integrative cancer therapies · 2017Review
- Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.Leukemia research · 2017Article
- Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.Leukemia & lymphoma · 2017Article
- Ruxolitinib dose management as a key to long-term treatment success.International journal of hematology · 2016Review
- Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.Advances in hematology · 2015Article
- Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.Future oncology (London, England) · 2015Review
- Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis.Leukemia & lymphoma · 2014Article
- Ruxolitinib for myelofibrosis--an update of its clinical effects.Clinical lymphoma, myeloma & leukemia · 2013Review
- Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival.Oncology (Williston Park, N.Y.) · 2013Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
23647081What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.